Please confirm you are human (Sign Up for free to never see this)
← Back to Search
The Use Of Immunomicelles To Treat Ovarian Cancer
David R. Khan, Shelby M. Phelps, J. Yarbrough, James D Woodyard, A. E. Muniz
Published 2019 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The use of nannocarriers in general for the delivery of cytotoxic agents to solid tumors is ideal as they have been shown to improve the overall pharmacological properties of otherwise low-molecular weight “free drugs”, or unencapsulated cytotoxic agents by altering drug pharmacokinetics and biodistribution/bioavailability .
This paper references
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
T. Hirano (2000)
Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells
C. Cárdenas (2016)
Overexpression of CD147 in ovarian cancer is initiated by the hypoxic microenvironment
H. Yang (2013)
GRP78 enabled micellebased glioma targeted drug delivery
D Ran (2017)
Mucins in cancer: function, prognosis and therapy
D. Kufe (2009)
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
M. C. Palanca-Wessels (2016)
The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.
C. Sarisozen (2014)
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
F. Perche (2012)
Micelle Delivery System Loaded with a Pharmaceutical Agent. US
VP Torchilin (2006)
Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly
Zhuoyang Fan (2015)
Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model
Bhushan S. Pattni (2016)
Hyaluronic acid conjugated micelles possessing CD44 targeting potential for gene delivery.
W. J. Lin (2017)
A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
B. Keam (2019)
Precision targeted therapy of ovarian cancer.
Justin Sapiezynski (2016)
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG.
Bhushan S. Pattni (2017)
Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.
M. Werner (2013)
Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters.
M. Muthu (2015)
Transferrintargeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells
AH Abouzeid (2014)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
T. Elbayoumi (2008)
Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil®.
Maximiliano Cagel (2017)
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Nirmala Chandralega Kampan (2015)
Design, Functionalization Strategies and Biomedical Applications of Targeted Biodegradable/Biocompatible Polymer‐Based Nanocarriers for Drug Delivery
J. Nicolas (2013)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
Clinical trials and progress with paclitaxel in ovarian cancer
S. Kumar (2010)
Recent Patents on Common Modifications Made to Traditional Micellar- Based Chemotherapeutics Designed to Improve Drug Delivery
D. R. Khan (2013)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
Prognostic, predictive and therapeutic Copyright
A Serrano Olvera (2006)
Receptor-targeted nanocarriers for therapeutic delivery to cancer
B. Yu (2010)
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. oncologist
B Keam (2019)
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
A. Serrano-Olvera (2006)
Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression
J. Stewart (2015)
Micelle Delivery System Loaded with a Pharmaceutical Agent
V P Torchilin (2006)
I. Judson (1993)
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
M. Felder (2014)
Chemotherapeutic Efficacy of Implantable Antineoplastic-Treatment Protocols in an Optimal Mouse Model for Human Ovarian Carcinoma Cell Targeting
J. Pantshwa (2018)
Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma.
R. Sawant (2014)
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
W. Depinto (2006)
Chemotherapeutic Effect of CD147 Antibody-labeled Micelles Encapsulating Doxorubicin Conjugate Targeting CD147-Expressing Carcinoma Cells.
T. Asakura (2018)
The transferrin receptor and the targeted delivery of therapeutic agents against cancer.
T. R. Daniels (2012)
Recent Advancements Involving Immunoliposomes to Target Breast Cancer
Antibody fragments as nanoparticle targeting ligands: a step in the right direction
Daniel A Richards (2017)